{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:53:24Z","timestamp":1790304804234,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gout is the most common arthritic disease in human but was long neglected and therapeutic options are not satisfying. However, with the recent approval of the urate transporter inhibitor lesinurad, gout treatment has experienced a major innovation. Here we show that lesinurad possesses considerable modulatory potency on peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3). Since gout has a strong association with metabolic diseases such as type 2 diabetes, this side-activity appears as very valuable contributing factor to the clinical efficacy profile of lesinurad. Importantly, despite robustly activating PPAR\u03b3<jats:italic>in vitro<\/jats:italic>, lesinurad lacked adipogenic activity, which seems due to differential coactivator recruitment and is characterized as selective PPAR\u03b3 modulator (sPPAR\u03b3M).<\/jats:p>","DOI":"10.1038\/s41598-018-31833-4","type":"journal-article","created":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T14:26:50Z","timestamp":1536071210000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Urate transporter inhibitor lesinurad is a selective peroxisome proliferator-activated receptor gamma modulator (sPPAR\u03b3M) in vitro"],"prefix":"10.1038","volume":"8","author":[{"given":"Pascal","family":"Heitel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Gellrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Heering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Goebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Kahnt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewgenij","family":"Proschak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Schubert-Zsilavecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5359-8128","authenticated-orcid":false,"given":"Daniel","family":"Merk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,10]]},"reference":[{"key":"31833_CR1","doi-asserted-by":"publisher","unstructured":"Pascart, T. & Liot\u00e9, F. Gout: state of the art after a decade of developments. Rheumatology (Oxford), https:\/\/doi.org\/10.1093\/rheumatology\/key002 (2018).","DOI":"10.1093\/rheumatology\/key002"},{"key":"31833_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13075-016-1107-x","volume":"18","author":"JN Miner","year":"2016","unstructured":"Miner, J. N. et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res. Ther. 18, 214 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"31833_CR3","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s00424-003-1089-9","volume":"447","author":"H Koepsell","year":"2004","unstructured":"Koepsell, H. & Endou, H. The SLC22 drug transporter family. Pflugers Archiv European Journal of Physiology 447, 666\u2013676 (2004).","journal-title":"Pflugers Archiv European Journal of Physiology"},{"key":"31833_CR4","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","volume":"76","author":"T Bardin","year":"2017","unstructured":"Bardin, T. et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann. Rheum. Dis. 76, 811\u2013820 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"31833_CR5","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/art.40159","volume":"69","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth, N. et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis Rheumatol. 69, 1903\u20131913 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"31833_CR6","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","volume":"56","author":"A-K Tausche","year":"2017","unstructured":"Tausche, A.-K. et al. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology (Oxford). 56, 2170\u20132178 (2017).","journal-title":"Rheumatology (Oxford)."},{"key":"31833_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/ckj\/sfx036","volume":"10","author":"MD Sanchez-Ni\u00f1o","year":"2017","unstructured":"Sanchez-Ni\u00f1o, M. D. et al. Lesinurad: what the nephrologist should know. Clin. Kidney J. 10, 679\u2013687 (2017).","journal-title":"Clin. Kidney J."},{"key":"31833_CR8","unstructured":"FDA. Zurampic Label. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209203s000lbl.pdf. (Accessed: 21st June 2018)."},{"key":"31833_CR9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1517\/13543776.2012.699042","volume":"22","author":"C Lamers","year":"2012","unstructured":"Lamers, C., Schubert-Zsilavecz, M. & Merk, D. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008\u2013present). Expert Opin. Ther. Pat. 22, 803\u2013841 (2012).","journal-title":"Expert Opin. Ther. Pat."},{"key":"31833_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bioorg.2018.02.009","volume":"77","author":"MJ Nanjan","year":"2018","unstructured":"Nanjan, M. J., Mohammed, M., Prashantha Kumar, B. R. & Chandrasekar, M. J. N. Thiazolidinediones as antidiabetic agents: A critical review. Bioorg. Chem. 77, 548\u2013567 (2018).","journal-title":"Bioorg. Chem."},{"key":"31833_CR11","doi-asserted-by":"crossref","first-page":"101310","DOI":"10.11131\/2017\/101310","volume":"4","author":"L Gellrich","year":"2017","unstructured":"Gellrich, L. & Merk, D. Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Modulation in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. Nucl. Recept. Res. 4, 101310 (2017).","journal-title":"Nucl. Recept. Res."},{"key":"31833_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.pharmthera.2015.11.011","volume":"157","author":"T Hanke","year":"2015","unstructured":"Hanke, T., Merk, D., Steinhilber, D., Geisslinger, G. & Schubert-Zsilavecz, M. Small molecules with anti-inflammatory properties in clinical development. Pharmacol. Ther. 157, 163\u201387 (2015).","journal-title":"Pharmacol. Ther."},{"key":"31833_CR13","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1021\/acs.jmedchem.6b01287","volume":"60","author":"E Proschak","year":"2017","unstructured":"Proschak, E., Heitel, P., Kalinowsky, L. & Merk, D. Opportunities and challenges for fatty acid mimetics in drug discovery. J. Med. Chem. 60, 5235\u20135266 (2017).","journal-title":"J. Med. Chem."},{"key":"31833_CR14","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1007\/BF01923636","volume":"30","author":"AA Santilli","year":"1974","unstructured":"Santilli, A. A., Scotese, A. C. & Tomarelli, R. M. A potent antihypercholesterolemic agent: [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14643). Experientia 30, 1110\u20131111 (1974).","journal-title":"Experientia"},{"key":"31833_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/13543776.2017.1272578","volume":"27","author":"J Pollinger","year":"2017","unstructured":"Pollinger, J. & Merk, D. Therapeutic applications of the versatile fatty acid mimetic WY14643. Expert Opin. Ther. Pat. 27, 517\u2013525 (2017).","journal-title":"Expert Opin. Ther. Pat."},{"key":"31833_CR16","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.4155\/fmc.15.87","volume":"7","author":"D Merk","year":"2015","unstructured":"Merk, D., Zettl, M., Steinhilber, D., Werz, O. & Schubert-Zsilavecz, M. Pirinixic acids: flexible fatty acid mimetics with various biological activities. Future Med. Chem. 7, 1597\u2013616 (2015).","journal-title":"Future Med. Chem."},{"key":"31833_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1073\/pnas.0811325106","volume":"106","author":"DR Artis","year":"2009","unstructured":"Artis, D. R. et al. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc. Natl. Acad. Sci. USA 106, 262\u20137 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"31833_CR18","doi-asserted-by":"publisher","first-page":"7703","DOI":"10.1021\/acs.jmedchem.7b00398","volume":"60","author":"J Schmidt","year":"2017","unstructured":"Schmidt, J. et al. A dual modulator of farnesoid X receptor and soluble epoxide hydrolase to counter nonalcoholic steatohepatitis. J. Med. Chem. 60, 7703\u20137724 (2017).","journal-title":"J. Med. Chem."},{"key":"31833_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1517\/17460441.2014.860129","volume":"9","author":"D Merk","year":"2014","unstructured":"Merk, D., Steinhilber, D. & Schubert-Zsilavecz, M. Characterizing ligands for farnesoid Xreceptor-available in vitro test systems for farnesoid Xreceptor modulator development. Expert Opin. Drug Discov. 9, 27\u201337 (2014).","journal-title":"Expert Opin. Drug Discov."},{"key":"31833_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cpdd.324","volume":"6","author":"M Gillen","year":"2017","unstructured":"Gillen, M. et al. Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and CYP Enzyme Substrates Sildenafil, Amlodipine, Tolbutamide, and Repaglinide. Clin. Pharmacol. Drug Dev. 6, 363\u2013376 (2017).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"31833_CR21","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.2147\/DDDT.S85193","volume":"9","author":"Z Shen","year":"2015","unstructured":"Shen, Z. et al. Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males. Drug Des. Devel. Ther. 9, 3423 (2015).","journal-title":"Drug Des. Devel. Ther."},{"key":"31833_CR22","doi-asserted-by":"crossref","unstructured":"Gregoire, F. M. et al. MBX-102\/JNJ39659100, a novel non-TZD selective partial PPAR-\u03b3 agonist lowers triglyceride independently of PPAR-\u03b1 activation. PPAR Res. 2009, (2009).","DOI":"10.1155\/2009\/706852"},{"key":"31833_CR23","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1194\/jlr.M200127-JLR200","volume":"43","author":"B Ljung","year":"2002","unstructured":"Ljung, B. et al. AZ 242, a novel PPAR\u03b1\/\u03b3 agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob\/ob mice and obese Zucker rats. J. Lipid Res. 43, 1855\u20131863 (2002).","journal-title":"J. Lipid Res."},{"key":"31833_CR24","doi-asserted-by":"crossref","unstructured":"Kunishima, C. et al. Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors. PPAR Res. 2007 (2007).","DOI":"10.1155\/2007\/36092"},{"key":"31833_CR25","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.3390\/ijms17081236","volume":"17","author":"A Pap","year":"2016","unstructured":"Pap, A., Cuaranta-Monroy, I., Peloquin, M. & Nagy, L. Is the Mouse a Good Model of Human PPAR\u03b3-Related Metabolic Diseases? Int. J. Mol. Sci. 17, 1236 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"31833_CR26","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.2147\/DDDT.S97959","volume":"11","author":"G Jones","year":"2017","unstructured":"Jones, G., Panova, E. & Day, R. Guideline development for the management of gout: role of combination therapy with a focus on lesinurad. Drug Des. Devel. Ther. 11, 3077\u20133081 (2017).","journal-title":"Drug Des. Devel. Ther."},{"key":"31833_CR27","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","volume":"56","author":"M Hui","year":"2017","unstructured":"Hui, M. et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology 56, e1\u2013e20 (2017).","journal-title":"Rheumatology"},{"key":"31833_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette, P. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis. 76, 29\u201342 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"31833_CR29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrrheum.2017.126","volume":"13","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth, N. et al. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat. Rev. Rheumatol. 13, 561\u2013568 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"31833_CR30","doi-asserted-by":"publisher","unstructured":"Yu, K.-H. et al. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. Int. J. Rheum. Dis., https:\/\/doi.org\/10.1111\/1756-185X.13266 (2018).","DOI":"10.1111\/1756-185X.13266"},{"key":"31833_CR31","doi-asserted-by":"crossref","unstructured":"Wang, Y. et al. Molecular medicine reports. Molecular Medicine Reports 14, (D.A. Spandidos, 2016).","DOI":"10.3892\/mmr.2016.5867"},{"key":"31833_CR32","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1210\/en.2005-0476","volume":"146","author":"A K\u00f6ster","year":"2005","unstructured":"K\u00f6ster, A. et al. Transgenic Angiopoietin-Like (Angptl)4 Overexpression and Targeted Disruption of Angptl4 and Angptl3: Regulation of Triglyceride Metabolism. Endocrinology 146, 4943\u20134950 (2005).","journal-title":"Endocrinology"},{"key":"31833_CR33","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2337\/diabetes.52.7.1779","volume":"52","author":"PA Kern","year":"2003","unstructured":"Kern, P. A., Gregorio, G. B. D., Lu, T., Rassouli, N. & Ranganathan, G. Adiponectin Expression From Human Adipose Tissue. Diabetes 52, 1779\u20131785 (2003).","journal-title":"Diabetes"},{"key":"31833_CR34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/35013000","volume":"405","author":"S Kersten","year":"2000","unstructured":"Kersten, S., Desvergne, B. & Wahli, W. Roles of PPARs in health and disease. Nature 405, 421\u20134 (2000).","journal-title":"Nature"},{"key":"31833_CR35","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2217\/fca-2017-0019","volume":"13","author":"L Han","year":"2017","unstructured":"Han, L., Shen, W.-J., Bittner, S., Kraemer, F. B. & Azhar, S. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-\u03b2\/\u03b4 and PPAR-\u03b3. Future Cardiol. 13, 279\u2013296 (2017).","journal-title":"Future Cardiol."},{"key":"31833_CR36","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.bbalip.2007.03.006","volume":"1771","author":"S Heikkinen","year":"2007","unstructured":"Heikkinen, S., Auwerx, J. & Argmann, C. A. PPAR\u03b3 in human and mouse physiology. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 1771, 999\u20131013 (2007).","journal-title":"Biochim. Biophys. Acta - Mol. Cell Biol. Lipids"},{"key":"31833_CR37","doi-asserted-by":"publisher","first-page":"R110","DOI":"10.1186\/ar4290","volume":"15","author":"MJ Ormseth","year":"2013","unstructured":"Ormseth, M. J. et al. Peroxisome proliferator-activated receptor \u03b3 agonist effect on rheumatoid arthritis: a randomized controlled trial. Arthritis Res. Ther. 15, R110 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"31833_CR38","doi-asserted-by":"publisher","first-page":"e000441","DOI":"10.1161\/JAHA.113.000441","volume":"2","author":"W Marder","year":"2013","unstructured":"Marder, W. et al. The Peroxisome Proliferator Activated Receptor- Pioglitazone Improves Vascular Function and Decreases Disease Activity in Patients With RheumatoidArthritis. J. Am. Heart Assoc. 2, e000441\u2013e000441 (2013).","journal-title":"J. Am. Heart Assoc."},{"key":"31833_CR39","doi-asserted-by":"publisher","first-page":"6577","DOI":"10.4238\/2014.August.28.2","volume":"13","author":"R-C Wang","year":"2014","unstructured":"Wang, R.-C. & Jiang, D.-M. PPAR-\u03b3 agonist pioglitazone affects rat gouty arthritis by regulating cytokines. Genet. Mol. Res. 13, 6577\u20136581 (2014).","journal-title":"Genet. Mol. Res."},{"key":"31833_CR40","unstructured":"Astra Zeneca. Zurampic Product Information. Available at: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-lesinurad-160920-pi.docx. (Accessed: 24th June 2018)."},{"key":"31833_CR41","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40261-016-0386-y","volume":"36","author":"Z Shen","year":"2016","unstructured":"Shen, Z. et al. In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters. Clin. Drug Investig. 36, 443\u201352 (2016).","journal-title":"Clin. Drug Investig."},{"key":"31833_CR42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejphar.2009.02.033","volume":"608","author":"K-AK Sohn","year":"2009","unstructured":"Sohn, K.-A. K. et al. S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats. Eur. J. Pharmacol. 608, 104\u201311 (2009).","journal-title":"Eur. J. Pharmacol."},{"key":"31833_CR43","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1254\/jphs.FP0050578","volume":"99","author":"T Fujimura","year":"2005","unstructured":"Fujimura, T. et al. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. J. Pharmacol. Sci. 99, 342\u201352 (2005).","journal-title":"J. Pharmacol. Sci."},{"key":"31833_CR44","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.bbalip.2007.01.008","volume":"1771","author":"S Yu","year":"2007","unstructured":"Yu, S. & Reddy, J. K. Transcription coactivators for peroxisome proliferator-activated receptors. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids 1771, 936\u2013951 (2007).","journal-title":"Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids"},{"key":"31833_CR45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1006\/bbrc.1997.7602","volume":"240","author":"J Mizukami","year":"1997","unstructured":"Mizukami, J. & Taniguchi, T. The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR gamma and CBP. Biochem. Biophys. Res. Commun. 240, 61\u20134 (1997).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"31833_CR46","doi-asserted-by":"publisher","first-page":"16906","DOI":"10.1074\/jbc.M200585200","volume":"277","author":"N Takahashi","year":"2002","unstructured":"Takahashi, N. et al. Overexpression and Ribozyme-mediated Targeting of Transcriptional Coactivators CREB-binding Protein and p300 Revealed Their Indispensable Roles in Adipocyte Differentiation through the Regulation of Peroxisome Proliferator-activated Receptor. J. Biol. Chem. 277, 16906\u201316912 (2002).","journal-title":"J. Biol. Chem."},{"key":"31833_CR47","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S0092-8674(02)01169-8","volume":"111","author":"F Picard","year":"2002","unstructured":"Picard, F. et al. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 111, 931\u201341 (2002).","journal-title":"Cell"},{"key":"31833_CR48","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1055\/s-0028-1102947","volume":"41","author":"T Inokuchi","year":"2009","unstructured":"Inokuchi, T. et al. Effects of benzbromarone and allopurinol on adiponectin in vivo and in vitro. Horm. Metab. Res. 41, 327\u2013332 (2009).","journal-title":"Horm. Metab. Res."},{"key":"31833_CR49","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1359-6446(05)03686-X","volume":"11","author":"CG Wermuth","year":"2006","unstructured":"Wermuth, C. G. Selective optimization of side activities: the SOSA approach. Drug Discov. Today 11, 160\u2013164 (2006).","journal-title":"Drug Discov. Today"},{"key":"31833_CR50","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1055\/s-2006-946680","volume":"72","author":"O Rau","year":"2006","unstructured":"Rau, O. et al. Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator-activated receptor gamma. Planta Med. 72, 881\u2013887 (2006).","journal-title":"Planta Med."},{"key":"31833_CR51","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.bmcl.2017.01.066","volume":"27","author":"P Heitel","year":"2017","unstructured":"Heitel, P., Achenbach, J., Moser, D., Proschak, E. & Merk, D. DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators. Bioorg. Med. Chem. Lett. 27, 1193\u20131198 (2017).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"31833_CR52","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1021\/acs.jmedchem.7b00903","volume":"60","author":"D Flesch","year":"2017","unstructured":"Flesch, D. et al. Non-acidic farnesoid X receptor modulators. J. Med. Chem. 60, 7199\u20137205 (2017).","journal-title":"J. Med. Chem."},{"key":"31833_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/srep14782","volume":"5","author":"J Schmidt","year":"2015","unstructured":"Schmidt, J. et al. NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid XReceptor. Sci. Rep. 5, 14782 (2015).","journal-title":"Sci. Rep."},{"key":"31833_CR54","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ab.2012.03.005","volume":"425","author":"K Zebisch","year":"2012","unstructured":"Zebisch, K., Voigt, V., Wabitsch, M. & Brandsch, M. Protocol for effective differentiation of 3T3-L1 cells to adipocytes. Anal. Biochem. 425, 88\u201390 (2012).","journal-title":"Anal. Biochem."},{"key":"31833_CR55","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1002\/jcc.20933","volume":"29","author":"P Labute","year":"2008","unstructured":"Labute, P. The generalized Born\/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J. Comput. Chem. 29, 1693\u20131698 (2008).","journal-title":"J. Comput. Chem."},{"key":"31833_CR56","doi-asserted-by":"crossref","unstructured":"Willson, T. M., Brown, P. J., Sternbach, D. D. & Henke, B. R. The PPARs: From Orphan Receptors to Drug Discovery. 43 (2000).","DOI":"10.1021\/jm990554g"},{"key":"31833_CR57","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/toxsci\/kfj173","volume":"91","author":"G Lemaire","year":"2006","unstructured":"Lemaire, G. et al. Identification of New Human Pregnane X Receptor Ligands among Pesticides Using a Stable Reporter Cell System. Toxicol. Sci. 91, 501\u2013509 (2006).","journal-title":"Toxicol. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31833-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31833-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31833-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T21:25:08Z","timestamp":1693862708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31833-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,10]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["31833"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-31833-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,10]]},"assertion":[{"value":"23 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13554"}}